Abstract
Background This study was conducted to determine the relationship between cardiometabolic phenotypes and atherogenic index of plasma in the Azar cohort population.
Methods This cross-sectional study included 9,515 participants aged 35 to 55, using data from the Azar Cohort Study. Metabolic syndrome was defined based on ATP III criteria. Participants were then classified into four cardiometabolic phenotypes by considering BMI and metabolic syndrome components: metabolically healthy normal weight (MHNW, BMI <25 kg/m²), metabolically unhealthy normal weight (MUHNW, BMI <25 kg/m²), metabolically healthy obese (MHO, BMI ≥25 kg/m²), and metabolically unhealthy obese (MUHO, BMI ≥25 kg/m²). AIP was calculated.
Result Among the subjects, 4,801 (50.5%) were metabolically healthy obese (MHO) and 2,680 (28.2%) were metabolically unhealthy obese (MUHO). High-risk AIP levels (>0.21) differed significantly across cardiometabolic phenotypes, with MUHNW (79.6%) and MUHO (64.6%) showing the highest proportions compared to MHNW (13.5%) and MHO (18.6%). After adjusting for confounders, multinomial logistic regression analysis showed individuals in the third tertile of AIP were 103.46 times more likely to be MUHNW (OR = 103.46, 95% CI: 52.82– 202.64), 55.77 times more likely to be MUHO (OR = 55.77, 95% CI: 45.65–68.12), and 2.22 times more likely to be MHO (OR = 2.22, 95% CI: 1.91–2.64) compared to the MHNW phenotype (p < 0.001 for all).
Conclusion The study demonstrates significant variation in high-risk AIP levels across cardiometabolic phenotypes, emphasizing the need for detailed metabolic health assessments beyond BMI to better predict cardiovascular risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the liver and gastrointestinal diseases research center (Grant No. 700/108 on 14 March 2016), Tabriz University of Medical Sciences. The funder had no role on the study design, data analysis, interpreting and writing the manuscript in this study. The Iranian Ministry of Health and Medical Education has contributed to the funding used in the PERSIAN Cohort through Grant no.700/534. The funder had no role on the study design, data analysis, interpreting and writing the manuscript in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethical Board of the Research Council of Tabriz University of Medical Sciences (No.IR.TBZMED.REC.1402.428).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from [Vice Chancellor for Research] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [Vice Chancellor for Research]
Abbreviation
- AIP
- Atherogenic index of plasma
- MHNW
- Metabolically healthy normal weight
- MUHNW
- Metabolically unhealthy normal weight
- MHO
- Metabolically healthy obese
- MUHO
- Metabolically unhealthy obese
- WSI
- Wealth Score Index
- MCA
- Multiple correspondence analysis
- METs
- Metabolic equivalents
- TG
- Triglyceride
- HDL-C
- High-density lipoprotein cholesterol
- LDL-C
- Low-density lipoprotein cholesterol
- FBG
- Fasting blood glucose
- WC
- Weist circumference
- HC
- Hip circumference
- BMI
- Body mass index
- SBP
- Systolic Blood Pressure
- DBP
- Diastolic Blood Pressure
